{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:49:48Z","timestamp":1789577388521,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We sought to determine the association of anti-Ro\/SS-A antibody with organ involvement and disease outcome in patients with systemic sclerosis (SSc).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, long-term study of a cohort of incident patients diagnosed with SSc and continuously followed at our rheumatology clinic during 1990\u20132018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Included were 105 patients with known anti-Ro\/SS-A antibody status, 92.4% female, mean age at diagnosis 52.0\u2009\u00b1\u200915.6\u2009years, and median follow-up of 10\u2009years; 64% were diagnosed with limited cutaneous SSc, 18% with diffuse cutaneous SSc, and 18% had SSc sin\u00e9 scleroderma or undetermined disease type. Anti-Ro\/SS-A antibody tested positive in 21% of patients. In univariate analysis, anti-Ro\/SS-A antibody positivity was significantly associated with SSc overlap with Sj\u00f6gren\u2019s syndrome (p\u2009&amp;lt;\u2009.001). Predicted forced vital capacity deterioration at last encounter was significantly associated with anti-Ro\/SS-A antibody positivity. In multivariate regression for anti-Ro\/SS-A antibody-positive SSc patients and disease outcome [adjusted for age\u2009&amp;gt;\u200950\u2009years, smoking, and baseline predicted forced vital capacity (pFVC)\u2009&amp;lt;\u200980%], positive anti-Ro\/SS-A antibody was significantly associated with a higher all-cause mortality rate (HR 5.17, CI 95%, 1.18\u201322.67, p\u2009=\u2009.029), and greater deterioration of pFVC defined as a decrement of last available pFVC compared to first available pFVC of \u226510% (HR 3.65, CI 95%, 1.07\u201312.38, p\u2009=\u2009.038).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anti-Ro\/SS-A antibody is an independent risk factor for worse pulmonary outcome and higher all-cause mortality in patients with SSc.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab118","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T06:01:52Z","timestamp":1639980112000},"page":"1086-1093","source":"Crossref","is-referenced-by-count":8,"title":["Anti-Ro\/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis"],"prefix":"10.1093","volume":"32","author":[{"given":"Katya","family":"Meridor","sequence":"first","affiliation":[{"name":"Department of Internal Medicine B, Meir Medical Center , Kfar Saba, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftach","family":"Sagy","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital , Petach Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Molad","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel"},{"name":"Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital , Petach Tikva, Israel"},{"name":"Clinical Research Center, Soroka University Medical Center , Beer Sheva, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev , Beer Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"2022101711273680400_R1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"2022101711273680400_R2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2022101711273680400_R3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"2022101711273680400_R4","first-page":"80","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"2022101711273680400_R5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ard.42.1.23","article-title":"Serological markers in progressive systemic sclerosis: clinical correlations","volume":"42","author":"Catoggio","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"2022101711273680400_R7","doi-asserted-by":"crossref","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2022101711273680400_R8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"2022101711273680400_R9","article-title":"Anti-SSA\/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study","volume":"32","author":"S\u00e1nchez-Montalv\u00e1","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022101711273680400_R10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/sji.12510","article-title":"The clinical relevance of antifibrillarin (anti-U3-RNP) autoantibodies in systemic sclerosis","volume":"85","author":"Tall","year":"2017","journal-title":"Scand J Immunol"},{"key":"2022101711273680400_R11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/rheumatology\/32.5.396","article-title":"The molecular basis of the SSA\/Ro antigens and the clinical significance of their autoantibodies","volume":"32","author":"Ben-Chetrit","year":"1993","journal-title":"Rheumatology"},{"key":"2022101711273680400_R12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/ard.56.11.667","article-title":"Prevalence and clinical relevance of 52-kDa and 60-kDa Ro\/SS-A autoantibodies in Japanese patients with systemic sclerosis","volume":"56","author":"Fujimoto","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R13","doi-asserted-by":"crossref","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2022101711273680400_R14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/art.1780260408","article-title":"Clinical and serologic study of Sj\u00f6gren\u2019s syndrome in patients with progressive systemic sclerosis","volume":"26","author":"Osial","year":"1983","journal-title":"Arthritis Rheum"},{"key":"2022101711273680400_R15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/rheumatology\/kep145","article-title":"Clinical significance of anti-Ro\/SSA-52 kDa antibodies - a retrospective monocentric study","volume":"48","author":"Hervier","year":"2009","journal-title":"Rheumatology"},{"key":"2022101711273680400_R16","doi-asserted-by":"crossref","DOI":"10.1186\/1740-2557-6-2","article-title":"Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis","volume":"6","author":"Parker","year":"2009","journal-title":"J Autoimmune Dis"},{"key":"2022101711273680400_R17","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022101711273680400_R18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00296-017-3718-1","article-title":"A review of the role and clinical utility of anti-Ro52\/TRIM21 in systemic autoimmunity","volume":"37","author":"Lee","year":"2017","journal-title":"Rheumatol Int"},{"key":"2022101711273680400_R19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2022101711273680400_R20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022101711273680400_R21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"2022101711273680400_R22","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3899\/jrheum.111582","article-title":"Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients","volume":"39","author":"Sampaio-Barros","year":"2012","journal-title":"J Rheumatol"},{"key":"2022101711273680400_R23","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R24","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022101711273680400_R25","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3899\/jrheum.140236","article-title":"Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects","volume":"41","author":"Diab","year":"2014","journal-title":"J Rheumatol"},{"key":"2022101711273680400_R26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"2022101711273680400_R28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.semarthrit.2011.10.004","article-title":"Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status","volume":"41","author":"Sime\u00f3n-Aznar","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2022101711273680400_R29","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0872-2","article-title":"Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis\u2013associated interstitial lung disease trials","volume":"17","author":"Khanna","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022101711273680400_R30","doi-asserted-by":"crossref","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2022101711273680400_R31","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022101711273680400_R32","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol Int"},{"key":"2022101711273680400_R34","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology"},{"key":"2022101711273680400_R35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology"},{"key":"2022101711273680400_R36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"2022101711273680400_R37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PLoS One"},{"key":"2022101711273680400_R38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"2022101711273680400_R39","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R40","first-page":"1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta- analysis of the literature","volume":"1","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022101711273680400_R41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022101711273680400_R42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4049\/jimmunol.179.1.26","article-title":"Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages","volume":"179","author":"Kong","year":"2007","journal-title":"J Immunol"},{"key":"2022101711273680400_R43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011776","article-title":"Self protection from anti-viral responses\u2014Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors","volume":"5","author":"Higgs","year":"2010","journal-title":"PLoS One"},{"key":"2022101711273680400_R44","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","article-title":"The E3 ubiquitin ligase Ro52 negatively regulates IFN-\u03b2 production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3","volume":"181","author":"Higgs","year":"2008","journal-title":"J Immunol"},{"key":"2022101711273680400_R45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bbrc.2011.12.010","article-title":"SS-A\/Ro52 promotes apoptosis by regulating Bcl-2 production","volume":"417","author":"Jauharoh","year":"2012","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab118\/41945260\/roab118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/6\/1086\/46543465\/roab118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/6\/1086\/46543465\/roab118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:56:08Z","timestamp":1666007768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/6\/1086\/6470340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12,20]]},"published-print":{"date-parts":[[2022,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab118","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2021,12,20]]}}}